The Diagnostic Imaging MRI modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of MRI across the healthcare continuum, including breast, neurological, cardiovascular, prostate imaging, and more.
May 9th 2024
Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
May 21, 2024
Register Now!
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
25th Annual International Lung Cancer Congress®
July 25-27, 2024
Register Now!
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
FDA Clears AI-Enabled Denoising Feature for DWI Sequences on Portable Brain MRI System
October 9th 2023In reportedly the eighth FDA 510(k) clearance for Hyperfine’s Swoop portable brain MRI device, clinicians will now have access to enhanced denoising capabilities with diffusion-weighted imaging (DWI) sequences.
MRI Study Identifies Pelvic Floor Parameters that May Lead to Postpartum Stress Urinary Incontinence
October 2nd 2023Researchers found that the combination of a retrovesicourethral angle, functional urethral length, and bladder funnel on MRI exams in primiparous women had a 94.7 percent AUC for predicting postpartum stress urinary incontinence (SUI).
Mammography-Based Deep Learning Model Facilitates Higher Breast Cancer Detection on Screening MRI
September 22nd 2023New research suggests the capability of a mammography-based deep learning model to identify women at high risk of breast cancer led to more than triple the cancer detection rate on breast MRI in comparison to traditional risk assessment tools.
AI Can Improve Tumor Mapping, Aid Patient Counseling in Focal Therapy for Prostate Cancer
August 31st 2023Wayne G. Brisbane, MD, of the University of California, Los Angeles, discussed the challenges of focal therapy for prostate cancer and how Unfold AI can help improve the accuracy of this treatment, as well as help counsel patients during the treatment decision process.
Study Reveals Tradeoffs Between Contrast-Enhanced Mammography and MRI for Supplemental Screening
August 16th 2023In a new study comparing standard breast MRI, abbreviated breast MRI and contrast-enhanced mammography in supplemental breast cancer screening, researchers found that MRI offered a greater than 14 percent higher cancer detection rate and a nearly 39 percent higher sensitivity rate than CEM.